THERANOVIR
Primary tabs
About your organization / profile
THERANOVIR is a preclinical innovative Health-Tech company of Research and Development of breakthrough therapies in 3 fields of closely related pathologies, Cancer, Obesity and associated metabolic diseases and Infectious Diseases by targeting a platform of signaling pathways regulated by the protein complex NRP-1/OBR, newly discovered by the CEO/CSO Dr. Zakia BELAID-SANDAL (PhD) ( Widow Choucair). THERANOVIR benefits from a global and exclusive license from INSERM transfert for the valuation of 2 families of granted patents in Europe, United States and Japan. THERANOVIR filed its own patent in January 2023. THERANOVIR is a winner of the Lab-SHAKER 2017 (Genopole), Onco-Entrepreneurs 2018 (Cancer Campus, Villejuif), HEC-Challenge+ 2019 (HEC Paris), Ilab2020 (Ministry of education and research), and Innov'up PIA 2021 (Ile-de-France region) competitions.
In the field on oncology, THERANOVIR is developing an immunotherapeutic antibody NOV2 with a unique mode of action through its ability to enter into the nucleus of cancer cells and degrade their DNA in a target-dependent manner based on the NRP-1/OBR complex induced by leptin and without any significant genotoxic effect on normal cells like human PBMC and Liver Cell line with a very high probability of reactivation of the anti-tumor immune response.
THERANOVIR is looking for seed funds between Q4 2023 and Q1 2024 allowing it to progress in the characterization of the lead NOV2 and enter the regulatory CMC phase.
In the field of Obesity, THERANOVIR generated anti-leptin antibody with promising effect of weight loss with a significant improvement of glucose tolerance in high fat died induced obesity model. THERANOVIR aims to propose this therapy to patient suffering from overweight associated to high level of circulating leptin as commonly named Leptin-resistance.
THERANOVIR is looking for a seed funds and partnering with experts in obesity like academic institutions, physicians and Pharma for a codevelopment.
THERANOVIR is looking for Investors who will help the company in the expansion of the team through the recruitment of a COO, business developper and engineers
Network (0)
There are no organizations in the network.
Recent activities
THERANOVIR is now a member of the EIC Accelerator France community.
ZAKIA BELAID-SANDAL has joined THERANOVIR.